News
Lilly raises full-year earnings forecasts on surging demand for weight-loss drug
Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's Wegovy.
Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Pharmaceutical Technology on MSN13h
Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly
Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...
While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...
The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback